PMID- 22612794
OWN - NLM
STAT- MEDLINE
DCOM- 20121221
LR  - 20211021
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 12
DP  - 2012 May 21
TI  - Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal 
      stroma tumor (GIST).
PG  - 186
LID - 10.1186/1471-2407-12-186 [doi]
AB  - BACKGROUND: The use of imatinib mesylate is associated with a progression free 
      survival of 41 months in first line treatment of metastatic or locally advanced 
      gastrointestinal stromal tumors (GIST) and other studies approved that adjuvant 
      imatinib treatment improves the recurrence-free survival in patients with GIST. 
      Current recommendations include 1 year adjuvant treatment in GIST patients at 
      risk but active studies explore different durations of treatment with an interval 
      of up to 5 years. While the most frequent adverse events (AEs) are blood count 
      alterations, abdominal discomfort and edema, the occurrence of grade 3 or 4 
      increase of AST or ALT is specified with 2.1% and 2.7% respectively. CASE 
      PRESENTATION: We report a 49-year old male with a gastrointestinal stromal tumor 
      (GIST) of the small bowel who developed liver cirrhosis under adjuvant imatinib 
      treatment. CONCLUSIONS: Our report supports the notion that imatinib-induced 
      hepatotoxicity may lead to acute liver damage with subsequent cirrhotic 
      remodelling. Patients developing grade 3 or 4 hepatotoxicity during imatinib 
      treatment should therefore be carefully evaluated for chronic liver disease.
FAU - Seidel, Christoph
AU  - Seidel C
AD  - Department of Hematology, Hemostasis, Oncology and Stem cell transplantation, 
      Hannover Medical School, Carl-Neuberg Strasse 1, 30625, Hannover, Germany. 
      seidel.christoph@mh-hannover.de
FAU - Fenner, Martin
AU  - Fenner M
FAU - Langer, Florian
AU  - Langer F
FAU - Bantel, Heike
AU  - Bantel H
FAU - Ganser, Arnold
AU  - Ganser A
FAU - Grunwald, Viktor
AU  - Grunwald V
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20120521
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzamides)
RN  - 0 (Piperazines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
SB  - IM
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Benzamides
MH  - Gastrointestinal Neoplasms/*complications/diagnosis/drug therapy
MH  - Humans
MH  - Imatinib Mesylate
MH  - Liver Cirrhosis/*chemically induced/diagnosis
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Piperazines/*adverse effects/therapeutic use
MH  - Protein Kinase Inhibitors/*adverse effects/therapeutic use
MH  - Pyrimidines/*adverse effects/therapeutic use
PMC - PMC3404905
EDAT- 2012/05/23 06:00
MHDA- 2012/12/22 06:00
PMCR- 2012/05/21
CRDT- 2012/05/23 06:00
PHST- 2011/10/04 00:00 [received]
PHST- 2012/05/21 00:00 [accepted]
PHST- 2012/05/23 06:00 [entrez]
PHST- 2012/05/23 06:00 [pubmed]
PHST- 2012/12/22 06:00 [medline]
PHST- 2012/05/21 00:00 [pmc-release]
AID - 1471-2407-12-186 [pii]
AID - 10.1186/1471-2407-12-186 [doi]
PST - epublish
SO  - BMC Cancer. 2012 May 21;12:186. doi: 10.1186/1471-2407-12-186.